NASDAQ:PMD - Psychemedics Stock Price, News, & Analysis

$10.35
+0.18 (+1.77 %)
(As of 06/18/2019 04:00 PM ET)
Today's Range
$9.7750
Now: $10.35
$10.35
50-Day Range
$9.53
MA: $10.32
$11.60
52-Week Range
$9.40
Now: $10.35
$22.31
Volume11,884 shs
Average Volume24,361 shs
Market Capitalization$57.00 million
P/E Ratio14.06
Dividend Yield7.08%
Beta0.76
Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States and internationally. The company's tests provide quantitative information that can indicate the approximate amount of drug ingested, as well as historical data, which can show a pattern of individual drug use over a longer period of time. It provides screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, PCP, amphetamines, synthetic cannabinoids, and benzodiazepines, as well as opiates, including heroin, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine. The company offers its services to employers for applicant and employee testing; treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use; and Fortune 500 companies and small to mid-size corporations, as well as school and government entities. Psychemedics Corporation was founded in 1985 and is headquartered in Acton, Massachusetts.

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PMD
CUSIPN/A
Phone978-206-8220

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$42.67 million
Cash Flow$1.4395 per share
Book Value$3.40 per share

Profitability

Net Income$4.58 million

Miscellaneous

Employees250
Market Cap$57.00 million
Next Earnings Date7/23/2019 (Estimated)
OptionableNot Optionable

Receive PMD News and Ratings via Email

Sign-up to receive the latest news and ratings for PMD and its competitors with MarketBeat's FREE daily newsletter.

Psychemedics (NASDAQ:PMD) Frequently Asked Questions

What is Psychemedics' stock symbol?

Psychemedics trades on the NASDAQ under the ticker symbol "PMD."

How often does Psychemedics pay dividends? What is the dividend yield for Psychemedics?

Psychemedics declared a quarterly dividend on Wednesday, April 24th. Shareholders of record on Tuesday, May 7th will be given a dividend of $0.18 per share on Friday, May 17th. This represents a $0.72 dividend on an annualized basis and a yield of 6.96%. The ex-dividend date is Monday, May 6th. View Psychemedics' Dividend History.

How were Psychemedics' earnings last quarter?

Psychemedics Corp. (NASDAQ:PMD) issued its quarterly earnings results on Tuesday, April, 23rd. The company reported $0.11 EPS for the quarter. The firm had revenue of $9.82 million for the quarter. Psychemedics had a return on equity of 21.41% and a net margin of 9.53%. View Psychemedics' Earnings History.

When is Psychemedics' next earnings date?

Psychemedics is scheduled to release their next quarterly earnings announcement on Tuesday, July 23rd 2019. View Earnings Estimates for Psychemedics.

Has Psychemedics been receiving favorable news coverage?

Media stories about PMD stock have been trending positive this week, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Psychemedics earned a media sentiment score of 2.6 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the stock's share price in the immediate future. View News Stories for Psychemedics.

Are investors shorting Psychemedics?

Psychemedics saw a increase in short interest during the month of May. As of May 15th, there was short interest totalling 13,600 shares, an increase of 67.9% from the April 15th total of 8,100 shares. Based on an average trading volume of 34,200 shares, the short-interest ratio is currently 0.4 days. Approximately 0.3% of the shares of the company are sold short. View Psychemedics' Current Options Chain.

Who are some of Psychemedics' key competitors?

What other stocks do shareholders of Psychemedics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Psychemedics investors own include Zynerba Pharmaceuticals (ZYNE), Uniti Group (UNIT), Verastem (VSTM), Athersys (ATHX), Cara Therapeutics (CARA), Exelixis (EXEL), GW Pharmaceuticals PLC- (GWPH), Uniqure (QURE), SCYNEXIS (SCYX) and Spectrum Pharmaceuticals (SPPI).

Who are Psychemedics' key executives?

Psychemedics' management team includes the folowing people:
  • Mr. Raymond C. Kubacki Jr., Chairman, CEO & Pres (Age 74)
  • Mr. Neil Lerner, VP of Fin. & Treasurer (Age 51)
  • Dr. Michael I. Schaffer, VP of Laboratory Operations (Age 74)
  • Dr. Werner A. Baumgartner Ph.D., Founder
  • Ms. Annette Baumgartner, Founder

Who are Psychemedics' major shareholders?

Psychemedics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Crawford Investment Counsel Inc. (5.64%), Tieton Capital Management LLC (5.47%), Deprince Race & Zollo Inc. (4.98%), Kennedy Capital Management Inc. (4.05%), Quantum Capital Management (1.02%) and Acadian Asset Management LLC (0.97%). Company insiders that own Psychemedics stock include Charles M Doucot, Michael I Schaffer, Neil Lerner and Raymond C Kubacki Jr. View Institutional Ownership Trends for Psychemedics.

Which major investors are selling Psychemedics stock?

PMD stock was sold by a variety of institutional investors in the last quarter, including Moors & Cabot Inc., Acadian Asset Management LLC, Deprince Race & Zollo Inc., Quantum Capital Management and Moors & Cabot Inc.. Company insiders that have sold Psychemedics company stock in the last year include Michael I Schaffer and Neil Lerner. View Insider Buying and Selling for Psychemedics.

Which major investors are buying Psychemedics stock?

PMD stock was purchased by a variety of institutional investors in the last quarter, including Kennedy Capital Management Inc., Tieton Capital Management LLC, Crawford Investment Counsel Inc., Alambic Investment Management L.P., Connors Investor Services Inc. and Punch & Associates Investment Management Inc.. Company insiders that have bought Psychemedics stock in the last two years include Charles M Doucot and Raymond C Kubacki Jr. View Insider Buying and Selling for Psychemedics.

How do I buy shares of Psychemedics?

Shares of PMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Psychemedics' stock price today?

One share of PMD stock can currently be purchased for approximately $10.35.

How big of a company is Psychemedics?

Psychemedics has a market capitalization of $57.00 million and generates $42.67 million in revenue each year. Psychemedics employs 250 workers across the globe.View Additional Information About Psychemedics.

What is Psychemedics' official website?

The official website for Psychemedics is http://www.psychemedics.com/.

How can I contact Psychemedics?

Psychemedics' mailing address is 289 GREAT ROAD, ACTON MA, 01720. The company can be reached via phone at 978-206-8220.


MarketBeat Community Rating for Psychemedics (NASDAQ PMD)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  111 (Vote Outperform)
Underperform Votes:  65 (Vote Underperform)
Total Votes:  176
MarketBeat's community ratings are surveys of what our community members think about Psychemedics and other stocks. Vote "Outperform" if you believe PMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel